Furthermore, data from the Center for Prostate Disease Research has shown a decrease in patients who initially present with metastatic disease from 19.8% in 1989 to 3.3% in 1998, which corresponds with the start of widespread PSA screening for CaP in the USA (17). This evidence concerns the gene KLK3 and metastatic neoplasm.